Skip to main content
Clinical Trials/NCT06578234
NCT06578234
Recruiting
Phase 4

Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses

Region Skane1 site in 1 country180 target enrollmentOctober 23, 2024

Overview

Phase
Phase 4
Intervention
Adenosine
Conditions
Chronic Coronary Syndrome
Sponsor
Region Skane
Enrollment
180
Locations
1
Primary Endpoint
Myocardial hyperemia
Status
Recruiting
Last Updated
10 months ago

Overview

Brief Summary

Adenosine is a commonly used pharmaceutical stressor at cardiac magnetic resonance examinations to assess suspected chronic coronary syndrome (CCS). However, several studies have reported that the current use of adenosine does not induce adequate hyperemic response in a substantial number of patients, leading to false diagnostics. The aim of this trial is to investigate the hyperemic effect of the standard dose of adenosine (140 microgram/kg/min) to the high dose of adenosine (210 microgram/kg/min) to improve the diagnostic methods using adenosine as a stressor and ultimately improve treatment decisions and patient prognosis in CCS.

Registry
clinicaltrials.gov
Start Date
October 23, 2024
End Date
December 31, 2026
Last Updated
10 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The subject has given their written consent to participate in the trial.
  • Are referred to Department of Clinical Physiology, Skåne University Hospital, for suspected or known CCS or heart failure
  • Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \>80 years old)
  • Matches the inclusion criteria for no known heart failure (group b) or known heart failure (group c)
  • No caffein intake \<24h prior to the examination
  • Healthy volunteers:
  • The subject has given their written consent to participate in the trial.
  • Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \>80 years old)
  • No caffein intake \<24h prior to the examination

Exclusion Criteria

  • Acute referral (in-house patients)
  • Clinically unstable
  • Acute chest pain
  • Severe or decompensated heart failure
  • Non sinus rhythm (e.g. atrial fibrillation)
  • Asthma or severe chronic obstructive pulmonary disease
  • Known chronic renal failure (eGFR \<45mL/min/1.73m2)
  • AV-block II or III
  • Left Bundle Branch Block
  • Systolic blood pressure \<90 mmHg or \>230 mmHg at rest

Arms & Interventions

Start standard dose adenosine followed by high dose adenosine

Subjects randomized to this arm will undergo the first stress perfusion acquisition with a dose of 140 μg/kg/min adenosine, followed by a second stress perfusion acquisition with the dose of 210 μg/kg/min adenosine.

Intervention: Adenosine

Start high dose adenosine followed by standard dose adenosine

Subjects randomized to this arm will undergo the first stress perfusion acquisition with a dose of 210 μg/kg/min adenosine, followed by a second stress perfusion acquisition with the dose of 140 μg/kg/min adenosine.

Intervention: Adenosine

Outcomes

Primary Outcomes

Myocardial hyperemia

Time Frame: During adenosine infusion, 4-6 minutes

The primary outcome measure is assessed by quantitative myocardial perfusion CMR imaging (ml/min/g).

Secondary Outcomes

  • Heart rate response(During adenosine infusion, 4-6 minutes)
  • Blood pressure response(During adenosine infusion, 4-6 minutes)
  • Symptoms(During adenosine infusion, 4-6 minutes)

Study Sites (1)

Loading locations...

Similar Trials